23andMe News and Activities

23andMe is a company listed under the stock ticker ME (US).

They are in:

• Biotechnology50%
• Healthcare50%

Acquisition, funding and merger involving 23andMe.

• Regeneron Pharmaceuticals has announced the acquisition of 23andMe  (posted on May 20 2025).
• 23andMe has filed for bankruptcy protection  (posted on March 25 2025).

View the org chart displaying its 17 main executives

Most searched biographies at 23andMe

• Anne Wojcicki, Chief Executive Officer
• Kent Hillyer, Vice President, Consumer Operations
• Tracy Keim, Chief Brand Officer

Popular executive movements at 23andMe

• Kael Reicin has joined the company as Chief Financial Officer  (posted on November 14 2025).
• Stephen Quake has joined the company as Director  (posted on November 14 2025).
• Brad Margus has joined the company as Director  (posted on November 14 2025).

Create your alert
to follow the executive moves at 23andMe.

23andMe has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by 23andMe

• 23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups - 23andMe Media Center
• 23andMe Research Institute Appoints Kael Reicin as Chief Financial Officer - 23andMe Media Center
• 23andMe Research Institute Appoints Privacy Advisory Board
• 23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors
• Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community - 23andMe Media Center
• TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets | 23andMe, Inc.
• 23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation | 23andMe, Inc.
• 23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process | 23andMe, Inc.
• 23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC | 23andMe, Inc.
• Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale | 23andMe, Inc.
• View more press releases Close

Social media about 23andMe

• 23andMe on Wikipedia, Google News & Yahoo Finance
• 23andMe on LinkedIn, X (Twitter) & YouTube